Brief: Argenx: Positive Topline Results From Phase 3 Adapt Oculus Trial Of Vyvgart In oMG
26/02/2026 05:31
Feb 26 (Reuters) - argenx SE ARGX.BR: ARGENX ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 ADAPT OCULUS TRIAL OF VYVGART IN OCULAR MYASTHENIA GRAVIS STUDY MEETS PRIMARY ENDPOINT WITH P-VALUE = 0.012 ADAPT OCULUS SHOWS SIGNIFICANT IMPROVEMENT IN MGII SCORES RESULTS SUPPORT PLANNED SBLA SUBMISSION TO FDA FOR OMG VYVGART WELL TOLERATED WITH FAVORABLE SAFETY PROFILE Source text: ID:nGNEvyn1t Further company coverage: ARGX.BR (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on argenx SE
See all newsArgenx falls after Vyvgart trial update on myositis drug, brokers remain positive
Brief: ArgenX Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit In Myositis And Sjogren’S Disease
Brief: argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Brief: Argenx Q1 Total Operating Income USD 1.313 Bln
Netherlands' Argenx Q1 net sales rise 63%, profit more than doubles